Eli Lilly, the global pharmaceutical giant, said the Therapeutic Goods Administration had approved the use of its Mounjaro weight-loss drug to treat moderate-to-severe obstructive sleep apnoea in ...

Eli Lilly and Company's stock price has increased by >1,000% since 2018—that is an astonishing achievement for a Pharma of its size, but there may well be more upside in store. It's all down to ...

The market for weight-loss drugs could see new entrants among existing biotech firms, with several drug candidates likely to be approved ... s obesity market will grow, particularly in China ...

Novo Nordisk has launched its blockbuster Wegovy weight-loss drug ... months after the drug was approved in the country. China estimates that more than half of the country’s adults are obese ...

As part of the license agreement with Novo, Deep Apple will be eligible to receive up to $812 million in payments, as well as ...

The success of Eli Lilly & Co.'s weight-loss and diabetes drugs has pushed ... as Lilly's stock soared after the company’s drug Mounjaro was approved by the Food and Drug Administration as ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?

Eli Lilly’s weight loss drug Zepbound outperformed competitor ... noting that he has greater difficulty getting tirzepatide approved for his patients, especially if they have suboptimal ...

China approved the company's anti-diabetes drug tirzepatide in May. Eli Lilly's obesity drug Zepbound is currently under review. A surge in demand for Novo Nordisk's diabetes and weight-loss ...

NEW YORK, May 20 (Reuters) - Online weight-loss company ... in Eli Lilly's (LLY.N), opens new tab rival Zepbound and Mounjaro, due to a regulatory exception allowing them during drug shortages.